Chapter 8

Valuation and Scenarios

At €63.88 Pernod Ricard trades at roughly 8x EV/EBITDA and 9.9x reported earnings — the deepest discount in the listed spirits group, on roughly double the dividend yield of any peer. That price sits close to what a permanently lower earning-power outcome is worth and well below what even a partial cyclical recovery implies. The gap the dislocation offers is real only if the demand problem is cyclical rather than structural; this chapter frames both outcomes and what would decide between them.

Where the price sits

Three of the prior chapters established the pieces of the valuation in isolation: the multiple compression that turned a 57% enterprise-value fall into a 70% equity fall (Damage Arithmetic), the sub-10% cash and dividend yields (Cash and the Dividend), and the reversed premiumisation behind the earnings decline (Demand Durability). Placed against the peer group, the multiple is unambiguous: Pernod Ricard is the cheapest large spirits name on every lens, and the cheapness is both absolute — against its own ~16-18x EV/EBITDA at the 2021–22 peak — and relative to peers trading today at 11–13x.

Sources: Pernod Ricard reported diluted EPS €6.45 and DPS €4.70 on the €63.88 close [1] [2]; EV/EBITDA per Damage Arithmetic; peer multiples and yields from market data (Diageo, Brown-Forman, Rémy Cointreau, Campari), as of February–July 2026. Pernod P/E is trailing (fwd ~11.1x on ~€5.77 consensus); Diageo P/E is forward.

The dividend yield tells the same story from a different angle. Pernod Ricard's 7.4% is roughly twice Diageo's 3.9%, Brown-Forman's 3.5% or Rémy Cointreau's 3.7%, and four times Campari's 1.8% [3]. A yield gap that wide is not a market oversight; it is the market pricing a materially higher chance that this dividend, unlike the others, is cut. The FY2025 payout was covered 0.94x by reported free cash flow (€1,201m paid against €1,133m generated) and only 1.12x on the recurring measure [4] — the tension the yield is compensating for.

Two scenarios

The valuation resolves into a single question already named as the through-line: is the earnings decline a cyclical trough that repairs, or a step down to permanently lower earning power? The two ends of that range produce very different values, and the current price is far closer to one of them.

The anchor is recurring net profit per share, which fell from €9.11 at the FY2023 peak to €7.26 in FY2025, with consensus near €5.77 for FY2026 [5]. The table below applies a normalized earnings level and a multiple to each scenario. The multiples are deliberately conservative — the upside cases re-rate only partway toward where peers trade today, not back to Pernod's own peak.

Source: derived from reported financials — recurring EPS path €9.11 (FY23) to €7.26 (FY25) [6] — and consensus; multiples are the author's assumptions, stated for transparency, not a forecast.

Source: scenario table above; current price €63.88 as of 3 July 2026. Derived from reported financials and consensus.

The reconciliation is the point. At €63.88 the market is paying almost exactly what the structural-base scenario is worth — earning power settling near the depressed FY2026 level with only modest growth. That is consistent with the reverse-DCF in Damage Arithmetic, which found the price implies roughly zero-to-two-percent perpetual free-cash-flow growth against a ~6.7% historical rate. Both lenses say the same thing: today's price underwrites near-permanent stagnation. It does not require a recovery to work as a value — it requires only that the business not decline. The upside, by contrast, is entirely a function of the demand read being cyclical: a partial repair toward the consensus median target of €88.5 is roughly +39%, and a fuller recovery is +80%, with a ~7% dividend collected each year in the interim if the payout holds.

The evidence on which scenario is unfolding is genuinely mixed, which is why the price is where it is. Q3 FY2026 showed group volumes back to +4% and organic sales at +0.1%, the first stabilisation after two years of decline [7]. That cuts toward cyclical. But volumes recovered while price/mix stayed negative — the downtrading signature (Demand Durability) — so the profit that matters has not yet turned, and management's own FY2027–2029 algorithm of +3% to +6% organic growth assumes a recovery it has not yet delivered [8].

Bull and bear on shared facts

The two cases are best set against the same numbers rather than competing narratives. Each row below is a fact from the filings; the disagreement is entirely about what it means.

Sources: EV/EBITDA and reverse-DCF per Damage Arithmetic; dividend cover [9]; Q3 volumes and organic sales [10]; family voting control per Ownership and Delivery.

No single row decides the case, and the honest reading is that they will not be decided by argument — only by the operating data over the next several quarters. The strongest fact for the bull is that the multiple has already compressed to a level that survives a no-growth outcome, so the downside is bounded unless earning power actually falls further or the dividend is cut. The strongest fact for the bear is that price/mix — the mechanism that carried premium-spirits earnings for a decade — is still going the wrong way, and a valuation that looks cheap on trailing earnings looks ordinary on a permanently lower base.

What to watch

The recovery mechanisms that matter for a value investor's ~18–24 month clock are the near-term ones: the end of US destocking and the resumption of duty-free cognac in China both plausibly land inside that window (Cognac and China). The structural-demand question — whether Western moderation is a cycle or a secular decline — will not be settled inside it, and that limitation should be stated rather than hidden. The list below is falsifiable: each item names the line to check, the filing it appears in, and the threshold that would move the read.

Sources: quarterly organic splits, China and US organic, and volumes from the Q3 FY2026 sales release [11]; FY2027–2029 organic algorithm [12]; net debt/EBITDA 3.3x and FCF €1.1bn [13]; proposed dividend of €4.70 per share [14]; consensus revisions from analyst estimates.

The dividend decision is the most compact tell. Held flat at €4.70 while free cash flow recovers, it signals a board that reads the trough as temporary; cut toward the roughly €3.63 that the stated ~50%-of-recurring-net-profit policy implies, and it confirms the coverage strain the yield already prices (Cash and the Dividend). Either way, the single most informative number to track is not the dividend or the multiple but price/mix: a return to positive price/mix is the evidence that would move this from the structural-base value where it trades toward the cyclical-recovery value it could reach.